LASTACAFT® (alcaftadine ophthalmic solution) 0.25%
LASTACAFT® (alcaftadine ophthalmic solution) 0.25%, approved by the U.S. Food and Drug Administration (FDA) in 2010, is a once-daily therapy for patients with itching due to allergic conjunctivitis.
LASTACAFT® is an ophthalmic solution containing 0.25% alcaftadine. Alcaftadine is an H1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells.
Proven to last through 16 hours with one drop daily, LASTACAFT® has also been shown to prevent itching at three minutes.
INDICATIONS AND USAGE
LASTACAFT® is an H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.
Important Safety Information
WARNINGS AND PRECAUTIONS
To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle.
Keep bottle tightly closed when not in use.
Patients should be advised not to wear a contact lens if their eye is red.
LASTACAFT® should not be used to treat contact lens-related irritation.
Remove contact lenses prior to instillation of LASTACAFT®. The preservative in LASTACAFT®, benzalkonium chloride, may be absorbed by soft contact lenses.
Lenses may be reinserted after 10 minutes following administration of LASTACAFT®. LASTACAFT® is for topical ophthalmic use only.
ADVERSE REACTIONS
The most frequent ocular adverse reactions, occurring in < 4% of LASTACAFT® treated eyes, were eye irritation, burning and/or stinging upon instillation, eye redness, and eye pruritus.
The most frequent non-ocular adverse reactions, occurring in < 3% of subjects with LASTACAFT® treated eyes, were nasopharyngitis, headache, and influenza. Some of these events were similar to the underlying disease being studied.